CISPLATIN+LENVATINIB	0.2809241723746194	None
CISPLATIN+LENVATINIB	0.2809241723746194	None
CISPLATIN+IFOSFAMIDE	0.2809241723746194	None
CISPLATIN+DENILEUKIN DIFTITOX	0.2809241723746194	None
CISPLATIN+MITOXANTRONE	0.2809241723746194	None
CISPLATIN+PACLITAXEL	0.2809241723746194	Cisplatin may increase the myelosuppressive activities of Paclitaxel.
CISPLATIN+TEMSIROLIMUS	0.2809241723746194	None
CISPLATIN+CYTARABINE	0.2809241723746194	None
CISPLATIN+CYCLOPHOSPHAMIDE	0.2809241723746194	Cyclophosphamide may increase the cardiotoxic activities of Cisplatin.
CISPLATIN+COPANLISIB	0.2809241723746194	None
CISPLATIN+BORTEZOMIB	0.2809241723746194	None
CISPLATIN+LENALIDOMIDE	0.2809241723746194	None
ERLOTINIB+BORTEZOMIB	-0.0	The metabolism of Erlotinib can be decreased when combined with Bortezomib.
ERLOTINIB+COPANLISIB	-0.0	None
ERLOTINIB+CYCLOPHOSPHAMIDE	-0.0	Cyclophosphamide may increase the cardiotoxic activities of Erlotinib.
ERLOTINIB+CYTARABINE	-0.0	None
ERLOTINIB+DENILEUKIN DIFTITOX	-0.0	None
ERLOTINIB+IFOSFAMIDE	-0.0	None
ERLOTINIB+LENALIDOMIDE	-0.0	None
ERLOTINIB+LENVATINIB	-0.0	None
ERLOTINIB+LENVATINIB	-0.0	None
DOXORUBICIN+TEMSIROLIMUS	-0.0	The serum concentration of Doxorubicin can be increased when it is combined with Temsirolimus.
VINORELBINE+TEMSIROLIMUS	-0.0	None
DOCETAXEL+LENALIDOMIDE	-0.0	The risk or severity of adverse effects can be increased when Docetaxel is combined with Lenalidomide.
DOXORUBICIN+PACLITAXEL	-0.0	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Doxorubicin.
DOXORUBICIN+PACLITAXEL	-0.0	The serum concentration of Doxorubicin can be increased when it is combined with Paclitaxel.
DOXORUBICIN+MITOXANTRONE	-0.0	The serum concentration of Doxorubicin can be increased when it is combined with Mitoxantrone.
DOXORUBICIN+LENVATINIB	-0.0	None
DOXORUBICIN+LENVATINIB	-0.0	None
DOXORUBICIN+LENALIDOMIDE	-0.0	None
DOXORUBICIN+IFOSFAMIDE	-0.0	The metabolism of Ifosfamide can be decreased when combined with Doxorubicin.
DOXORUBICIN+DENILEUKIN DIFTITOX	-0.0	None
DOXORUBICIN+CYTARABINE	-0.0	None
DOXORUBICIN+CYCLOPHOSPHAMIDE	-0.0	Cyclophosphamide may increase the cardiotoxic activities of Doxorubicin.
DOXORUBICIN+CYCLOPHOSPHAMIDE	-0.0	The serum concentration of Doxorubicin can be increased when it is combined with Cyclophosphamide.
DOXORUBICIN+COPANLISIB	-0.0	None
DOXORUBICIN+BORTEZOMIB	-0.0	The metabolism of Doxorubicin can be decreased when combined with Bortezomib.
DOXORUBICIN+BORTEZOMIB	-0.0	The serum concentration of Doxorubicin can be increased when it is combined with Bortezomib.
DOCETAXEL+TEMSIROLIMUS	-0.0	The risk or severity of adverse effects can be increased when Docetaxel is combined with Temsirolimus.
DOCETAXEL+PACLITAXEL	-0.0	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Docetaxel.
DOCETAXEL+MITOXANTRONE	-0.0	The risk or severity of adverse effects can be increased when Docetaxel is combined with Mitoxantrone.
ERLOTINIB+MITOXANTRONE	-0.0	None
ERLOTINIB+PACLITAXEL	-0.0	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Erlotinib.
ERLOTINIB+TEMSIROLIMUS	-0.0	None
GEMCITABINE+IFOSFAMIDE	-0.0	None
GEFITINIB+MITOXANTRONE	-0.0	None
GEFITINIB+PACLITAXEL	-0.0	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Gefitinib.
GEFITINIB+TEMSIROLIMUS	-0.0	None
GEMCITABINE+BORTEZOMIB	-0.0	None
GEMCITABINE+CYCLOPHOSPHAMIDE	-0.0	Cyclophosphamide may increase the cardiotoxic activities of Gemcitabine.
GEMCITABINE+DENILEUKIN DIFTITOX	-0.0	None
GEMCITABINE+LENALIDOMIDE	-0.0	None
GEFITINIB+LENALIDOMIDE	-0.0	None
GEMCITABINE+LENVATINIB	-0.0	None
GEMCITABINE+LENVATINIB	-0.0	None
GEMCITABINE+MITOXANTRONE	-0.0	None
GEMCITABINE+PACLITAXEL	-0.0	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Gemcitabine.
ICOTINIB+BORTEZOMIB	-0.0	The metabolism of Icotinib can be decreased when combined with Bortezomib.
ICOTINIB+COPANLISIB	-0.0	None
ICOTINIB+CYCLOPHOSPHAMIDE	-0.0	None
GEFITINIB+LENVATINIB	-0.0	None
GEFITINIB+LENVATINIB	-0.0	None
GEFITINIB+IFOSFAMIDE	-0.0	None
ETOPOSIDE+BORTEZOMIB	-0.0	The metabolism of Etoposide can be decreased when combined with Bortezomib.
ETOPOSIDE+LENVATINIB	-0.0	None
ETOPOSIDE+LENVATINIB	-0.0	None
ETOPOSIDE+COPANLISIB	-0.0	None
ETOPOSIDE+CYCLOPHOSPHAMIDE	-0.0	Cyclophosphamide may increase the cardiotoxic activities of Etoposide.
ETOPOSIDE+CYTARABINE	-0.0	None
ETOPOSIDE+DENILEUKIN DIFTITOX	-0.0	None
ETOPOSIDE+IFOSFAMIDE	-0.0	None
ETOPOSIDE+LENALIDOMIDE	-0.0	None
ETOPOSIDE+MITOXANTRONE	-0.0	None
GEFITINIB+DENILEUKIN DIFTITOX	-0.0	None
ETOPOSIDE+PACLITAXEL	-0.0	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Etoposide.
ETOPOSIDE+TEMSIROLIMUS	-0.0	None
GEFITINIB+BORTEZOMIB	-0.0	The metabolism of Gefitinib can be decreased when combined with Bortezomib.
GEFITINIB+COPANLISIB	-0.0	None
GEFITINIB+CYCLOPHOSPHAMIDE	-0.0	Cyclophosphamide may increase the cardiotoxic activities of Gefitinib.
GEFITINIB+CYTARABINE	-0.0	None
DOCETAXEL+LENVATINIB	-0.0	The risk or severity of adverse effects can be increased when Docetaxel is combined with Lenvatinib.
DOCETAXEL+LENVATINIB	-0.0	The risk or severity of adverse effects can be increased when Docetaxel is combined with Lenvatinib.
DOCETAXEL+BORTEZOMIB	-0.0	The risk or severity of adverse effects can be increased when Docetaxel is combined with Bortezomib.
DOCETAXEL+IFOSFAMIDE	-0.0	The risk or severity of adverse effects can be increased when Docetaxel is combined with Ifosfamide.
BEVACIZUMAB+LENVATINIB	-0.0	Bevacizumab may increase the cardiotoxic activities of Lenvatinib.
BEVACIZUMAB+LENVATINIB	-0.0	Bevacizumab may increase the cardiotoxic activities of Lenvatinib.
BEVACIZUMAB+IFOSFAMIDE	-0.0	Bevacizumab may increase the cardiotoxic activities of Ifosfamide.
BEVACIZUMAB+DENILEUKIN DIFTITOX	-0.0	Bevacizumab may increase the cardiotoxic activities of Denileukin diftitox.
BEVACIZUMAB+CYTARABINE	-0.0	Bevacizumab may increase the cardiotoxic activities of Cytarabine.
BEVACIZUMAB+CYCLOPHOSPHAMIDE	-0.0	Bevacizumab may increase the cardiotoxic activities of Cyclophosphamide.
BEVACIZUMAB+COPANLISIB	-0.0	None
BEVACIZUMAB+BORTEZOMIB	-0.0	Bevacizumab may increase the cardiotoxic activities of Bortezomib.
ALECTINIB+TEMSIROLIMUS	-0.0	None
ALECTINIB+PACLITAXEL	-0.0	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Alectinib.
ALECTINIB+MITOXANTRONE	-0.0	None
ALECTINIB+LENVATINIB	-0.0	None
ALECTINIB+LENVATINIB	-0.0	None
ALECTINIB+LENALIDOMIDE	-0.0	None
ALECTINIB+IFOSFAMIDE	-0.0	None
ALECTINIB+DENILEUKIN DIFTITOX	-0.0	None
ALECTINIB+CYTARABINE	-0.0	None
ALECTINIB+CYCLOPHOSPHAMIDE	-0.0	Cyclophosphamide may increase the cardiotoxic activities of Alectinib.
ALECTINIB+COPANLISIB	-0.0	None
ALECTINIB+BORTEZOMIB	-0.0	None
AFATINIB+TEMSIROLIMUS	-0.0	The serum concentration of Afatinib can be increased when it is combined with Temsirolimus.
AFATINIB+PACLITAXEL	-0.0	The serum concentration of Afatinib can be increased when it is combined with Paclitaxel.
AFATINIB+MITOXANTRONE	-0.0	The serum concentration of Afatinib can be decreased when it is combined with Mitoxantrone.
AFATINIB+LENVATINIB	-0.0	None
AFATINIB+LENVATINIB	-0.0	None
AFATINIB+LENALIDOMIDE	-0.0	None
AFATINIB+IFOSFAMIDE	-0.0	None
AFATINIB+DENILEUKIN DIFTITOX	-0.0	None
AFATINIB+CYTARABINE	-0.0	None
AFATINIB+CYCLOPHOSPHAMIDE	-0.0	The serum concentration of Afatinib can be increased when it is combined with Cyclophosphamide.
AFATINIB+COPANLISIB	-0.0	None
BEVACIZUMAB+LENALIDOMIDE	-0.0	Bevacizumab may increase the cardiotoxic activities of Lenalidomide.
BEVACIZUMAB+MITOXANTRONE	-0.0	Bevacizumab may increase the cardiotoxic activities of Mitoxantrone.
DOCETAXEL+DENILEUKIN DIFTITOX	-0.0	The risk or severity of adverse effects can be increased when Docetaxel is combined with Denileukin diftitox.
BEVACIZUMAB+PACLITAXEL	-0.0	Bevacizumab may increase the cardiotoxic activities of Paclitaxel.
DOCETAXEL+CYTARABINE	-0.0	The risk or severity of adverse effects can be increased when Docetaxel is combined with Cytarabine.
DOCETAXEL+CYCLOPHOSPHAMIDE	-0.0	Cyclophosphamide may increase the cardiotoxic activities of Docetaxel.
DOCETAXEL+COPANLISIB	-0.0	None
ICOTINIB+DENILEUKIN DIFTITOX	-0.0	None
CRIZOTINIB+PACLITAXEL	-0.0	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Crizotinib.
CRIZOTINIB+MITOXANTRONE	-0.0	None
CRIZOTINIB+LENVATINIB	-0.0	Crizotinib may increase the QTc-prolonging activities of Lenvatinib.
CRIZOTINIB+LENVATINIB	-0.0	Crizotinib may increase the QTc-prolonging activities of Lenvatinib.
CRIZOTINIB+LENALIDOMIDE	-0.0	None
CRIZOTINIB+IFOSFAMIDE	-0.0	The serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Crizotinib resulting in a loss in efficacy.
CRIZOTINIB+DENILEUKIN DIFTITOX	-0.0	None
CRIZOTINIB+CYTARABINE	-0.0	The metabolism of Cytarabine can be decreased when combined with Crizotinib.
CRIZOTINIB+CYCLOPHOSPHAMIDE	-0.0	Cyclophosphamide may increase the cardiotoxic activities of Crizotinib.
CRIZOTINIB+BORTEZOMIB	-0.0	The metabolism of Crizotinib can be decreased when combined with Bortezomib.
CARBOPLATIN+PACLITAXEL	-0.0	Carboplatin may increase the myelosuppressive activities of Paclitaxel.
CARBOPLATIN+LENVATINIB	-0.0	None
CARBOPLATIN+LENVATINIB	-0.0	None
CARBOPLATIN+BORTEZOMIB	-0.0	None
BRIGATINIB+TEMSIROLIMUS	-0.0	None
BRIGATINIB+PACLITAXEL	-0.0	None
BRIGATINIB+MITOXANTRONE	-0.0	None
BRIGATINIB+LENVATINIB	-0.0	None
BRIGATINIB+LENVATINIB	-0.0	None
BRIGATINIB+LENALIDOMIDE	-0.0	None
BRIGATINIB+IFOSFAMIDE	-0.0	None
BRIGATINIB+DENILEUKIN DIFTITOX	-0.0	None
BRIGATINIB+CYTARABINE	-0.0	None
BRIGATINIB+CYCLOPHOSPHAMIDE	-0.0	None
BRIGATINIB+COPANLISIB	-0.0	None
BRIGATINIB+BORTEZOMIB	-0.0	The metabolism of Brigatinib can be decreased when combined with Bortezomib.
ICOTINIB+CYTARABINE	-0.0	None
ICOTINIB+IFOSFAMIDE	-0.0	None
VINORELBINE+PACLITAXEL	-0.0	Paclitaxel may increase the neurotoxic activities of Vinorelbine.
PORFIMER+CYCLOPHOSPHAMIDE	-0.0	None
RAMUCIRUMAB+IFOSFAMIDE	-0.0	None
RAMUCIRUMAB+DENILEUKIN DIFTITOX	-0.0	None
RAMUCIRUMAB+CYTARABINE	-0.0	None
RAMUCIRUMAB+CYCLOPHOSPHAMIDE	-0.0	Cyclophosphamide may increase the cardiotoxic activities of Ramucirumab.
RAMUCIRUMAB+COPANLISIB	-0.0	None
RAMUCIRUMAB+BORTEZOMIB	-0.0	None
PORFIMER+TEMSIROLIMUS	-0.0	None
PORFIMER+PACLITAXEL	-0.0	None
PORFIMER+MITOXANTRONE	-0.0	None
PORFIMER+LENVATINIB	-0.0	None
PORFIMER+LENVATINIB	-0.0	None
PORFIMER+LENALIDOMIDE	-0.0	None
PORFIMER+IFOSFAMIDE	-0.0	None
PORFIMER+DENILEUKIN DIFTITOX	-0.0	None
PORFIMER+CYTARABINE	-0.0	None
PORFIMER+COPANLISIB	-0.0	None
RAMUCIRUMAB+LENVATINIB	-0.0	None
RAMUCIRUMAB+LENVATINIB	-0.0	None
PORFIMER+BORTEZOMIB	-0.0	None
PEMETREXED+TEMSIROLIMUS	-0.0	None
PEMETREXED+PACLITAXEL	-0.0	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Pemetrexed.
PEMETREXED+MITOXANTRONE	-0.0	None
PEMETREXED+LENVATINIB	-0.0	None
PEMETREXED+LENVATINIB	-0.0	None
PEMETREXED+LENALIDOMIDE	-0.0	None
PEMETREXED+IFOSFAMIDE	-0.0	None
PEMETREXED+DENILEUKIN DIFTITOX	-0.0	None
PEMETREXED+CYTARABINE	-0.0	None
PEMETREXED+CYCLOPHOSPHAMIDE	-0.0	Cyclophosphamide may increase the cardiotoxic activities of Pemetrexed.
PEMETREXED+COPANLISIB	-0.0	None
PEMETREXED+BORTEZOMIB	-0.0	None
OSIMERTINIB+TEMSIROLIMUS	-0.0	The serum concentration of Temsirolimus can be increased when it is combined with Osimertinib.
OSIMERTINIB+PACLITAXEL	-0.0	The serum concentration of Paclitaxel can be increased when it is combined with Osimertinib.
RAMUCIRUMAB+LENALIDOMIDE	-0.0	None
RAMUCIRUMAB+MITOXANTRONE	-0.0	None
ICOTINIB+LENALIDOMIDE	-0.0	None
VINCRISTINE+IFOSFAMIDE	-0.0	None
VINORELBINE+MITOXANTRONE	-0.0	None
VINORELBINE+LENVATINIB	-0.0	None
VINORELBINE+LENVATINIB	-0.0	None
VINORELBINE+LENALIDOMIDE	-0.0	None
VINORELBINE+IFOSFAMIDE	-0.0	None
VINORELBINE+DENILEUKIN DIFTITOX	-0.0	None
VINORELBINE+CYTARABINE	-0.0	None
VINORELBINE+CYCLOPHOSPHAMIDE	-0.0	Cyclophosphamide may increase the cardiotoxic activities of Vinorelbine.
VINORELBINE+COPANLISIB	-0.0	None
VINORELBINE+BORTEZOMIB	-0.0	The metabolism of Vinorelbine can be decreased when combined with Bortezomib.
VINCRISTINE+TEMSIROLIMUS	-0.0	The excretion of Vincristine can be decreased when combined with Temsirolimus.
VINCRISTINE+PACLITAXEL	-0.0	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Vincristine.
VINCRISTINE+PACLITAXEL	-0.0	The excretion of Vincristine can be decreased when combined with Paclitaxel.
VINCRISTINE+MITOXANTRONE	-0.0	The serum concentration of Vincristine can be decreased when it is combined with Mitoxantrone.
VINCRISTINE+LENVATINIB	-0.0	None
VINCRISTINE+LENVATINIB	-0.0	None
VINCRISTINE+LENALIDOMIDE	-0.0	None
VINCRISTINE+DENILEUKIN DIFTITOX	-0.0	None
RAMUCIRUMAB+PACLITAXEL	-0.0	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Ramucirumab.
VINCRISTINE+CYTARABINE	-0.0	None
VINCRISTINE+CYCLOPHOSPHAMIDE	-0.0	Cyclophosphamide may increase the cardiotoxic activities of Vincristine.
VINCRISTINE+CYCLOPHOSPHAMIDE	-0.0	The excretion of Vincristine can be decreased when combined with Cyclophosphamide.
VINCRISTINE+COPANLISIB	-0.0	None
VINCRISTINE+BORTEZOMIB	-0.0	The metabolism of Vincristine can be decreased when combined with Bortezomib.
TOPOTECAN+PACLITAXEL	-0.0	The serum concentration of Topotecan can be increased when it is combined with Paclitaxel.
TOPOTECAN+MITOXANTRONE	-0.0	The serum concentration of Topotecan can be increased when it is combined with Mitoxantrone.
TOPOTECAN+LENVATINIB	-0.0	None
TOPOTECAN+LENVATINIB	-0.0	None
TOPOTECAN+LENALIDOMIDE	-0.0	None
TOPOTECAN+IFOSFAMIDE	-0.0	None
TOPOTECAN+DENILEUKIN DIFTITOX	-0.0	None
TOPOTECAN+CYTARABINE	-0.0	None
TOPOTECAN+CYCLOPHOSPHAMIDE	-0.0	The serum concentration of Topotecan can be increased when it is combined with Cyclophosphamide.
TOPOTECAN+BORTEZOMIB	-0.0	None
RAMUCIRUMAB+TEMSIROLIMUS	-0.0	None
OSIMERTINIB+MITOXANTRONE	-0.0	None
OSIMERTINIB+LENVATINIB	-0.0	The serum concentration of Lenvatinib can be increased when it is combined with Osimertinib.
OSIMERTINIB+LENVATINIB	-0.0	The serum concentration of Lenvatinib can be increased when it is combined with Osimertinib.
OSIMERTINIB+LENALIDOMIDE	-0.0	None
METHOTREXATE+BORTEZOMIB	-0.0	None
MITOMYCIN+CYTARABINE	-0.0	None
MITOMYCIN+CYCLOPHOSPHAMIDE	-0.0	Cyclophosphamide may increase the cardiotoxic activities of Mitomycin.
MITOMYCIN+COPANLISIB	-0.0	None
MITOMYCIN+BORTEZOMIB	-0.0	None
METHOTREXATE+TEMSIROLIMUS	-0.0	None
METHOTREXATE+PACLITAXEL	-0.0	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Methotrexate.
METHOTREXATE+MITOXANTRONE	-0.0	None
METHOTREXATE+LENVATINIB	-0.0	None
METHOTREXATE+LENVATINIB	-0.0	None
METHOTREXATE+LENALIDOMIDE	-0.0	None
METHOTREXATE+IFOSFAMIDE	-0.0	None
METHOTREXATE+DENILEUKIN DIFTITOX	-0.0	None
METHOTREXATE+CYTARABINE	-0.0	None
METHOTREXATE+CYCLOPHOSPHAMIDE	-0.0	Cyclophosphamide may increase the cardiotoxic activities of Methotrexate.
METHOTREXATE+COPANLISIB	-0.0	None
IRINOTECAN+TEMSIROLIMUS	-0.0	None
OSIMERTINIB+IFOSFAMIDE	-0.0	The serum concentration of Ifosfamide can be increased when it is combined with Osimertinib.
IRINOTECAN+PACLITAXEL	-0.0	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Irinotecan.
IRINOTECAN+MITOXANTRONE	-0.0	None
IRINOTECAN+LENVATINIB	-0.0	None
IRINOTECAN+LENVATINIB	-0.0	None
IRINOTECAN+LENALIDOMIDE	-0.0	None
IRINOTECAN+IFOSFAMIDE	-0.0	None
IRINOTECAN+DENILEUKIN DIFTITOX	-0.0	None
IRINOTECAN+CYTARABINE	-0.0	None
IRINOTECAN+CYCLOPHOSPHAMIDE	-0.0	Cyclophosphamide may increase the cardiotoxic activities of Irinotecan.
IRINOTECAN+COPANLISIB	-0.0	None
IRINOTECAN+BORTEZOMIB	-0.0	The metabolism of Irinotecan can be decreased when combined with Bortezomib.
ICOTINIB+TEMSIROLIMUS	-0.0	None
ICOTINIB+PACLITAXEL	-0.0	None
ICOTINIB+MITOXANTRONE	-0.0	None
ICOTINIB+LENVATINIB	-0.0	None
ICOTINIB+LENVATINIB	-0.0	None
MITOMYCIN+DENILEUKIN DIFTITOX	-0.0	None
MITOMYCIN+IFOSFAMIDE	-0.0	None
MITOMYCIN+LENALIDOMIDE	-0.0	None
MITOMYCIN+LENVATINIB	-0.0	None
MITOMYCIN+LENVATINIB	-0.0	None
OSIMERTINIB+DENILEUKIN DIFTITOX	-0.0	None
OSIMERTINIB+CYTARABINE	-0.0	The serum concentration of Cytarabine can be increased when it is combined with Osimertinib.
OSIMERTINIB+CYCLOPHOSPHAMIDE	-0.0	Cyclophosphamide may increase the cardiotoxic activities of Osimertinib.
OSIMERTINIB+COPANLISIB	-0.0	The serum concentration of Copanlisib can be increased when it is combined with Osimertinib.
OSIMERTINIB+BORTEZOMIB	-0.0	The serum concentration of Bortezomib can be increased when it is combined with Osimertinib.
OLMUTINIB+TEMSIROLIMUS	-0.0	None
OLMUTINIB+PACLITAXEL	-0.0	None
OLMUTINIB+MITOXANTRONE	-0.0	None
OLMUTINIB+LENVATINIB	-0.0	None
OLMUTINIB+LENVATINIB	-0.0	None
OLMUTINIB+LENALIDOMIDE	-0.0	None
OLMUTINIB+IFOSFAMIDE	-0.0	None
OLMUTINIB+DENILEUKIN DIFTITOX	-0.0	None
OLMUTINIB+CYTARABINE	-0.0	None
OLMUTINIB+CYCLOPHOSPHAMIDE	-0.0	None
OLMUTINIB+COPANLISIB	-0.0	None
OLMUTINIB+BORTEZOMIB	-0.0	None
NINTEDANIB+TEMSIROLIMUS	-0.0	The serum concentration of Nintedanib can be increased when it is combined with Temsirolimus.
NINTEDANIB+MITOXANTRONE	-0.0	The serum concentration of Nintedanib can be increased when it is combined with Mitoxantrone.
NINTEDANIB+LENVATINIB	-0.0	None
NINTEDANIB+LENVATINIB	-0.0	None
NINTEDANIB+LENALIDOMIDE	-0.0	None
NINTEDANIB+IFOSFAMIDE	-0.0	None
NINTEDANIB+DENILEUKIN DIFTITOX	-0.0	None
NINTEDANIB+CYTARABINE	-0.0	None
NINTEDANIB+CYCLOPHOSPHAMIDE	-0.0	Cyclophosphamide may increase the cardiotoxic activities of Nintedanib.
NINTEDANIB+COPANLISIB	-0.0	None
NINTEDANIB+BORTEZOMIB	-0.0	None
MITOMYCIN+TEMSIROLIMUS	-0.0	None
MITOMYCIN+PACLITAXEL	-0.0	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Mitomycin.
MITOMYCIN+MITOXANTRONE	-0.0	None
AFATINIB+BORTEZOMIB	-0.0	None
